This paper describes an unusual kindred with familial hypercholesterolemia in which one-third of the relatives with a mutant LDL receptor gene have normal plasma cholesterol concentrations. The proband, a 9-yr-old boy with a plasma cholesterol value > 500 mg/dl, is homozygous for a point mutation that changes Serl56 to Leu in the LDL receptor. This substitution in the fourth repeat of the ligand binding domain slows the transport of the protein to the cell surface. The defective receptor cannot bind LDL, which contains apo B-100, but it does bind a-migrating VLDL, which contains apo E in addition to apo B-100. Although the mother is heterozygous for this mutation, her LDL-cholesterol concentration is consistently in the 28th percentile for the population. Through direct examination of genomic DNA, we identified the mutant gene in heterozygous form in 17 of the mother's relatives, five of whom had normal LDL-cholesterol values. The pedigree was consistent with dominant transmission of a single gene that ameliorates or suppresses the hypercholesterolemic effect of the LDL receptor mutation. Through linkage analysis, we excluded the possibility that this suppressor gene was an allele at the LDL receptor locus. We also excluded the genes for the two ligands for the LDL receptor, apo B-100 and apo E. The existence of this putative suppressor gene may explain the occasional observation of normal LDL-cholesterol concentrations in heterozygotes for LDL receptor mutations.
Introduction
Mutations in the gene for the LDL receptor produce familial hypercholesterolemia (FH) ,' a disease that is transmitted in an autosomal codominant fashion (1) . Individuals who inherit one mutant LDL receptor gene (FH heterozygotes) generally have two to threefold elevations in plasma LDL-cholesterol concentrations and develop symptomatic coronary artery dis-ease in the fourth to sixth decades. Individuals with two mutant LDL receptor genes (FH homozygotes) have LDL-cholesterol values that are sixfold or more above normal, and they frequently have symptomatic atherosclerosis in childhood.
When the concentration of LDL-cholesterol in plasma is used as a marker, the penetrance of the FH gene is -90% in FH heterozygotes (1, 2 The LDL receptor binds two protein components of lipoproteins, apo B-100 and apo E (5) . A single molecule of apo B-100 is found on each LDL particle and its precursors, VLDL and intermediate density lipoprotein (IDL) . IDL is also referred to as ,B-VLDL. Apo E, which binds to the receptor with higher affinity than apo B-100, is present in multiple copies on each f,-VLDL particle. Certain mutations in the ligand binding domain of the LDL receptor eliminate LDL binding without affecting j3-VLDL binding (6, 7) .
In this paper we report a detailed analysis of a kindred with FH caused by a point mutation that results in a single amino acid substitution in the ligand binding domain of the LDL receptor. This kindred is referred to as the P. family. 6 out of 18 heterozygous individuals had normal concentrations of LDL-cholesterol despite the presence of one mutant LDL receptor gene. Pedigree analysis is consistent with the transmission of a dominant gene that suppresses the expression of hypercholesterolemia when it is inherited together with the mutant LDL receptor gene.
Methods
Materials. Human LDL (8) , rabbit ,B-VLDL (9) , human lipoproteindeficient serum (8) , and mouse anti-LDL receptor MAb IgG-C7 (10) were prepared as described in the indicated reference. Restriction enzymes were obtained from New England Biolabs (Beverly, MA). Thermus aquaticus DNA polymerase was obtained from Perkin Elmer methionine (-1,000 Ci/mmol) were obtained from New England Nuclear (Boston, MA). [y-32P]ATP (7,000 Ci/mmol) for end-labeling oligonucleotides was purchased from ICN Radiochemicals (Irvine, CA). Oligonucleotides were synthesized on a DNA synthesizer and genomic DNA was purified using a nucleic acid extractor; both machines were obtained from Applied Biosystems (models 380A and 340A, respectively; Foster City, CA). DNA was amplified using the DNA thermal cycler from Perkin Elmer Cetus.
LDL receptor assays. Diploid fibroblasts obtained from skin biopsy specimens were grown in monolayer culture at 37°C in a 5% CO2 incubator. About 2.5 X I04 cells from stock cultures were seeded into 60-mm Petri dishes according to a standard protocol and cultured for 5 d (8) . Maximal synthesis of LDL receptors was induced by incubation in human lipoprotein-deficient serum for 24-48 h before study as described elsewhere (8) . Cell surface binding of'251I-LDL, '251-f3-VLDL, and '25I-IgG-C7 by monolayers at 4°C was determined as described (6) . Metabolism of '25I-LDL by monolayers at 37°C was measured as described (8) . Immunochemical analysis of [35S]methionine-labeled LDL receptors was performed as described (11) .
DNA sequencing of mutant LDL receptor allele. The 3' region of exon 4 of the LDL receptor gene was amplified by the polymerase chain reaction (PCR) using I ,ug of genomic DNA from a normal individual and FH 848. Two oligonucleotides homologous to sequences in exon 4 and the exon 4/intron 4 junction were used for the amplification reaction (see legend to Fig. 3 ). The samples were denatured at 95°C for 1 min and then annealed and extended at 68°C for 5 min. After 35 cycles of amplification, the DNA was fractionated on a 6% polyacrylamide gel in buffer A (50 mM Tris-borate, 90 mM boric acid, 2 mM sodium EDTA at pH 8.3). A 220-bp fragment was excised from the gel, and the DNA was purified. Sequence analysis was performed according to the Maxam and Gilbert method (12 Determination ofapo B genotypes. The hypervariable minisatellite located 181 bp 3' of the poly(A) addition site of the human apo B gene (19) was selectively amplified by PCR from 1 Mg of genomic DNA using 32P-end-labeled (13) oligonucleotide HV-1 (5'-TATGGAGG-GAAATATT-T-TGCAAAAA-3') and unlabeled oligonucleotide HV-2 (5'-CAAATACAATTCCTGAGATCAATAA-3') as described above. After 35 cycles of amplification, 5 Ml of the reaction mixture (total volume of 50 MAl) was subjected to electrophoresis on a 10% denaturing polyacrylamide gel in buffer A at 200 V for 24 h at room temperature. Autoradiography was performed at room temperature for 1 h using XAR-5 film.
Haplotype analysis ofapo E-CI-CII gene complex. Genomic DNA (1 Mg) was subjected to PCR amplification using 32P-end-labeled oligonucleotides HP-I (5'-AGGAACAGGGATTGCTCACTCGGGG-3') and unlabeled oligonucleotide HP-2 (5'-TCTTCCTGACTCTGTGG-GGTCCTCA-3'). These oligonucleotides flank a previously described RFLP site, Hpa I, located 5' ofthe apo Cl gene (20) . After 35 cycles of amplification the entire reaction product was size fractionated on a 6% nondenaturing gel in buffer A at 200 V for 1.5 h at room temperature. The gel was subjected to autoradiography and a 186-bp fragment was excised and purified. A total of -80 ng (80,000 dpm) was subjected to restriction enzyme digestion with Hpa I in the buffer suggested by the manufacturer. The digested products were electrophoresed on a 6% nondenaturing polyacrylamide gel in buffer A at 200 V for 2 h at room temperature. Apo E isoforms were determined by immunoblot analysis of 5 Ml of plasma using monoclonal antibodies specific for apo E2, E3, and E4 (21) . The isoform studies were kindly performed by Professor Dr. Gerd Utermann (Institute for Medical Biology and Genetics, University of Innsbruck, Innsbruck, Austria). Genotypes were constructed for selected members of the pedigree using the results of the Hpa I RFLP analysis and the apo E isoform data. Table I compares the metabolism of '25I-LDL at 37°C in fibroblasts from FH homozygote 848, his mother, with that of one normal individual studied simultaneously. The FH 848 cells bound -3% of the normal amount of LDL at the surface. After 5 h, the cells internalized and degraded < 1% ofthe normal amount of 125I-LDL. These findings are consistent with the presence of two mutant alleles at the LDL receptor locus (1) . In fibroblasts from the mother of FH 848, the amount of '251I-LDL binding, internalization, and degradation were 40, 23, and 62% of normal, respectively. These findings are consistent with the presence of one normal allele and one defective allele at the LDL receptor locus (1) .
To determine whether the FH 848 cells synthesize defective LDL receptors, the cells were incubated with [35S]-methionine for 2 h, after which they were washed and incubated with unlabeled methionine for 0, 1.2, or 2 h. The cells were harvested and solubilized with detergent, and the LDL receptors were immunoprecipitated and subjected to SDS-PAGE and autoradiography. The normal LDL receptor is synthesized as a precursor with an apparent Mr of 120,000, which is processed in the Golgi complex to a mature form with an apparent M, of 160,000 (1 1). This processed form is rapidly transported to the cell surface. In normal cells at the zero time point, approximately equal amounts of the precursor and mature forms of the LDL receptor were present (Fig. 1, left (Fig. 2 A) . The total amount of binding was 40% of normal at 4°C. This mutant receptor was unable to bind '25I-LDL (Fig. 2 B) '25I-f3-VLDL (Fig. 2 C) (Fig. 3) . In exon 4, in the region encoding the fourth repeat in the ligand binding domain (4), a cytosine at nucleotide position 530 was changed to a thymidine, changing the codon for amino acid 156 from serine to leucine (Fig. 3) . This amino acid is part of the highly conserved SerAspGlu sequence that is found in each repeat of Functional and biosynthetic studies ofthe LDL receptor in fibroblasts from the mother of FH 848 confirmed that she was an FH heterozygote (Table I and Fig. 1 ). However, the mother's plasma LDL-cholesterol concentrations were repeatedly in the normal range. Her LDL-cholesterol value was -100 mg/dl on two determinations; these values are at the 28th percentile for her age and sex. The father of FH 848, also an obligate FH heterozygote, died at age 32 of a sudden death, caused by acute myocardial infarction as documented by autopsy. Over a 7-yr period before his death (1974) (1975) (1976) (1977) (1978) (1979) (1980) (1981) , the father had nine total plasma cholesterol determinations, the average of which was 305 mg/dl. Fig. 4 shows the pedigree of the mother's family, and the data are summarized in Table II received one copy of this mutant chromosome from his father and another copy from his mother. Although consanguinity was denied, it seems likely that the mother and father had a common ancestor because they both originated from neighboring villages in Puerto Rico.
Among the mother's relatives, 12 were hypercholesterolemic (closed triangles above the 95th percentile in Fig. 5 Table II ). The LDL-cholesterol values for individuals 111-20 (age 8), IV-2 (age 2), and IV-3 (age 1) were estimated as 70% of the total plasma cholesterol level (Table II) .
(including the mother) who inherited haplotype 32 had plasma LDL-cholesterol levels in the normal range (solid triangles within shaded area of Fig. 5 ).
The individuals who inherited haplotype 32, and presumably the mutant LDL receptor gene, are indicated by half-filled symbols in the pedigree of Fig. 4 . The subset of these FH heterozygotes with normal LDL-cholesterol levels is indicated by an asterisk. Two ofthese normocholesterolemic individuals were the siblings of the proband, designated III-21 and III-22. These two boys (age 16 and 10, respectively) each inherited one copy of the LDL receptor-bearing chromosome that contained haplotype 32. They each had total cholesterol concentrations < 190 mg/dl (Table II) .
To confirm that the individuals with haplotype 32 possessed the nucleotide substitution in the coding region of the LDL receptor gene, we performed PCR on exon 4 in genomic DNA, spotted the amplified products on nitrocellulose filters, and hybridized the filters with 32P-labeled oligonucleotide probes that were specific either for the normal or mutant sequence (Fig. 6 ). DNA from a relative without haplotype 32 amplifiedfrom l,ugof genomic DNA from selected members of the P. family using oligonucleotides SP 6 IN (5'-CCCCCAAGACGTGCTCCCAGGACGA-3') and SP 5 lA ('-ACGCCCCGCCCCCACCCTGCCCCGC-3'), as described in Methods. One-tenth of the amplified product (5 Ml) was denatured prior to dot-blotting onto duplicate nylon membranes. The filters were subsequently hybridized with 32P-end-labeled oligo 848B (5'-AAGATGGCTCGGATGAGTG-3'), an oligonucleotide homologous to the normal sequence, or 32P-end-labeled oligo 848C(5'-AA-GATGGCTTGGATGAGTG3'), an oligonucleotide homologous to the mutant sequence of FH 848. individuals all inherited one copy of the mutant LDL receptor gene. Among the individuals demonstrated to have the mutant LDL receptor gene in Fig. 6 , six had normal LDL-cholesterol levels (designated by asterisks). These included the proband's mother (II-14) and his two brothers (III-21 and III-22). It also included one ofthe mother's brothers (II-15), sisters , and sister's children (III-7) .
The simplest explanation for the distribution of LDL-cholesterol values in the P. family postulates the transmission of a dominant gene that suppresses the LDL-elevating effect of the LDL receptor mutation. Proceeding on the basis of this hypothesis, we sought to determine whether any of the genes whose products are known to affect the interaction of LDL with its receptor cosegregated with this suppressor phenotype. We therefore sought for genetic linkage between the suppressor gene and the gene for the LDL receptor itself or the genes for its two ligands, apo B-100 and apo E.
Haplotype analysis excluded the possibility that the suppression of the LDL receptor defect in FH heterozygotes was caused by the normal allele at the LDL receptor locus. For example, the two siblings of the propositus, III-21 and III-22, both had suppressed LDL-cholesterol values, yet they inherited different normal LDL receptor alleles (haplotype 11 and haplotype 29, respectively) (Fig. 7) . The mother's brother and sister (II-4 and II-15) who also had suppressed LDL-cholesterol values inherited a third haplotype (haplotype 2). The haplotype 11 gene, which was associated with low LDL-cholesterols in patient III-2 1, was associated with high LDL cholesterols in patients II-11 and II-6 (Fig. 7) . These data exclude the possibility that a "superactive" normal LDL receptor allele is responsible for suppressing the effect of the mutant LDL receptor gene. Table II ); the percentiles for LDL-cholesterol were determined from sex-and age-matched control data (22) . LDL receptor gene haplotypes were determined as described in Methods. Apo B genotypes were determined as described in Fig. 8 . The apo E isoforms were determined by immunoblotting with antibodies specific for apo E2, E3, and E4 (21 To trace the apo B gene in the P. family, we used PCR to explore a region at the 3' end of the gene that contains a variable number of tandem repeats (VNTR) (Fig. 8 A) (19) . In the immediate family of the propositus, seven different chromosomes bearing the apo B gene were identified on the basis of VNTR of different length (Fig. 8) . The linkage data excluded cosegregation of the apo B gene with the LDL-lowering gene. For example, the mother of the propositus (11) (12) (13) (14) has two alleles at the apo B locus, designated 4 and 5 (Fig. 8 C) . One of her sons (III-2 1) inherited allele 5 and the other (III-22) inherited allele 4. These two boys also inherited different alleles from the father (alleles 1 and 6, respectively) (Fig. 8 C) . Although they did not share an apo B gene, both ofthem had low LDL-cholesterol values. Among the mother's siblings, several comparisons excluded linkage of the apo B gene to the low LDL-cholesterols. For example, individual II-4 had a low LDL-cholesterol, yet she did not share any apo B genes with her sister (11) (12) (13) (14) who had a similarly low cholesterol (Fig. 8 B) . Similarly, individuals II-4 and II-1 1 had the same alleles at the apo B locus, yet one had a high LDL-cholesterol and the other a low LDL-cholesterol.
The gene for apo E, a known ligand for the LDL receptor, was polymorphic in the mother's family, but none of the apo E isoforms (21) cosegregated with the low LDL-cholesterol (Fig. 7) . Thus, the mother (II-14) was heterozygous for isoforms E4 and E3. Her two heterozygous sons with low LDLcholesterol values were each homozygous, one for E3 and the other E4. Three of the mother's siblings with E4/E3 heterozygosity had high LDL-cholesterols (subjects II-1, II-6, and II-7) (Fig. 7) . Thus, the low LDL-cholesterol values in the propositus' mother (11) (12) (13) (14) cannot be attributable to her E4/E3 heterozygosity.
It is possible that the LDL suppressor effect is due to the inheritance of a mutation at the apo E locus that is independent of the polymorphisms responsible for the common apo E isoforms. To exclude this possibility, we constructed haplotypes in the region of chromosome 19 containing the closely spaced apo E, apo CI, and apo CII loci (20) , using an RFLP 5' of the apo CI gene and the results of the apo E isoform determinations. These data excluded cosegregation of LDL levels with any gene in this region. For example, the propositus' mother was heterozygous for genotype 1 and genotype 4 (Fig.  7) . One of her heterozygous sons inherited her genotype 1-bearing chromosome (III-2 1) and the other inherited her genotype 4-bearing chromosome (III-22), yet both ofthese sons had low LDL-cholesterol values (Fig. 7) .
Discussion
This paper describes a kindred, the P. family, that includes 18 FH heterozygotes who have a bimodal distribution of plasma LDL-cholesterol concentrations. 12 of these heterozygotes have LDL-cholesterol concentrations above the 95th percentile, as would be expected for FH. 6 ofthe 18 FH heterozygotes have plasma LDL-cholesterols within the normal range (Fig.  5) . The pedigree is consistent with the transmission of a single dominant gene that ameliorates or suppresses the cholesterolelevating effect ofthe LDL receptor mutation (Fig. 4) . Thus, in generation II, subjects 11-4, 11-14, and II-15 are postulated to possess the suppressor gene. II-4 and II-14 passed it on to their offspring. The other FH heterozygotes in generation II did not show evidence for the suppressor gene, and none of their offspring in generations III or IV showed suppression of hypercholesterolemia.
Through linkage analysis, we have excluded the three most obvious candidates for suppressors of hypercholesterolemia caused by defective LDL receptors, i.e., the normal LDL receptor and its two ligands, apo B-100 and apo E. If a suppressor gene is present, it must produce another protein that influences plasma LDL-cholesterol concentrations. To suggest other candidate genes, it is necessary to consider the mechanism by which the LtDL receptor influences plasma LDL concentrations.
The LDL receptor mediates the removal from blood of lipoproteins that carry endogenous cholesterol (1). The receptor binds lipoproteins that contain apo B-100 or apo E and mediates the uptake of these lipoproteins by receptor-mediated endocytosis, primarily in the liver, and their subsequent destruction in lysosomes. Endogenous cholesterol transport begins when the liver secretes triglyceride-rich VLDL which contains both apo E and apo B-100. The apo E on VLDL is relatively inactive in LDL receptor binding, apparently because it is masked by other proteins, the apo Cs (25, 26) . After the triglycerides of VLDL have been removed by lipoprotein lipase in capillaries of adipose tissue and muscle, the VLDL particle shrinks, becomes relatively enriched in cholesterol, and is designated as IDL or f,-VLDL. During this conversion the apo Cs leave the particle, the apo E is activated, and IDL acquires the ability to bind to LDL receptors with extremely high affinity via apo E. As a result of this binding, most IDL particles are cleared from blood by binding to hepatic LDL receptors (27) . Some IDL particles escape hepatic uptake and 662 Hobbs, Leitersdorf; Leffert, Cryer, Brown, and Goldstein undergo further conversion to LDL. This conversion, which is facilitated by hepatic lipase (28) , is accompanied by the loss of apo E (29).
A defect in LDL receptors elevates plasma LDL through a combination of overproduction and inefficient catabolism (27) . Overproduction results from a reduction in the hepatic clearance of IDL particles, thereby causing an increased conversion to LDL. Inefficient catabolism of LDL is a direct result of the reduction in LDL receptors. Given this scheme, the putative gene for LDL suppression must either lower the rate of VLDL secretion or enhance the rate of clearance of IDL or LDL.
It is probably significant that the mutant LDL receptor in the P. family retains its ability to bind (3-VLDL, which is a form of IDL. This binding is not sufficient in itself to prevent the increase in plasma LDL concentrations because most of the FH heterozygotes in this family have elevated LDL values. Moreover, FH 848, the homozygous propositus, has markedly elevated LDL values despite the ability of his receptors to bind IDL. However, this binding does create the possibility that some individuals may be able to escape hypercholesterolemia.
A reasonable hypothesis is that individuals with the suppressor gene can use the IDL-binding capacity of the mutant LDL receptor to enhance IDL clearance, whereas the hypercholesterolemic individuals lack this ability. One possibility is that the individuals with the suppressor gene have a delay in the conversion of IDL to LDL. This would allow the IDL to remain in the circulation longer, with its apo E attached. It would then have a greater opportunity to be removed from the circulation by the normal and defective LDL receptors before it is converted to LDL. Such an event might occur if the individuals with the suppressor gene had a relatively low activity of hepatic lipase. Another possibility is that these subjects have an abnormal form of apo C that is unable to inhibit the binding activity of apo E on IDL. This abnormality cannot involve apo CI or apo CII because of the linkage analysis (Fig. 7) . However, we cannot exclude an alteration of apo CIII. To date, we have been unable to obtain an informative segregation analysis using ten polymorphisms at the apo AI-CIII-AIV locus (30) in the relevant members of the P. family.
A final possibility relates to the regulation of LDL receptor production. The suppressor gene might lead to increased expression of LDL receptors in the liver. Such an effect could result from a direct stimulation of LDL receptor gene transcription, or indirectly as a result ofan alteration in the metabolism ofbile acids or cholesterol in a fashion that would lead to a reduction in hepatic cholesterol concentrations, which in turn would induce LDL receptors (1) .
We cannot exclude the possibility that VLDL production and/or secretion is reduced by the suppressor gene. The factors that control the production and secretion of VLDL are poorly understood and specific products regulating these processes have not been identified.
An important question is whether the putative LDL suppressor gene lowers LDL-cholesterol values in the absence of an LDL receptor mutation. The maternal grandmother (1) (2) and one of the mother's siblings (II-9) had LDL-cholesterol concentrations that were below the 5th percentile. This raises the possibility that the suppressor gene reduces LDL-cholesterol below normal in individuals with normal LDL receptors. The number of subjects in this pedigree is not sufficient to allow this hypothesis to be tested conclusively. It is possible, however, that the gene observed here as a suppressor of hypercholesterolemia is one of the mutations that produce dominantly inherited hypobetaliproteinemia in individuals with normal LDL receptors. Certain mutations in the apo B gene are postulated to have this cholesterol-lowering effect (31) , but because linkage with the apo B gene was excluded, such a mutation cannot account for the findings in the current pedigree.
